Abstract 17P
Background
Gastric cancer is a multifaceted condition exhibiting varied responses to treatment, emphasizing the need for tailored therapeutic strategies. This study endeavors to elucidate the cellular interactions and molecular mechanisms that underlie the response to Sintilimab plus SOX (fluorouracil plus oxaliplatin) therapy among gastric cancer patients.
Methods
Single-cell sequencing and multiplex immunohistochemistry (mIHC) were employed to elucidate the spatial characteristics linked to the response of gastric cancer to chemo- and immuno- treatment. By integration of mIHC, feature extraction, and machine learning algorithms, we elucidated the intricate interactions between cellular populations and developed a Support Vector Machine (SVM) model for the prediction of treatment response.
Results
We initially discovered a significant correlation between apical membrane cells and resistance to fluorouracil and oxaliplatin, both crucial components of the treatment regimen. This prompted us to delve into the involvement of apical membrane cells in treatment response. Through a thorough examination of cell interactions, we noted substantial connections between apical membrane cells and resident macrophages. Further analysis of ligand-receptor interactions unveiled specific molecular associations, with TGFB1-HSPB1 and LTF-S100A14 interactions standing out, indicating potential signaling pathways implicated in treatment response. To forecast treatment response, we developed an SVM model integrating six markers (DUOX2, HSPB1, S100A14, C1QA, TGFB1, and LTF), which demonstrated outstanding predictive capacity, achieving high area under the curve (AUC) values of 0.93 in the exploration cohort and 0.84 in the validation cohort.
Conclusions
Our research underscored the importance of integrating multi-omics data alongside spatial information in predictive model, holding the promise of steering personalized therapeutic decisions and enhancing treatment efficacy.
Legal entity responsible for the study
The First Affiliated Hospital, School of Medicine, Zhejiang University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
137P - First-in-human results from a Phase I dose-escalation study of VSV-GP (BI 1831169) in patients with advanced solid tumors
Presenter: Stephane Champiat
Session: Poster Display
138P - Generation of frameshift mutated TGF_R2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1/GM-CSF
Presenter: Else Inderberg
Session: Poster Display
139P - Safety and clinical activity of a novel anti-CCR8 antibody (LM-108) as a single agent or in combination with pembrolizumab in patients with advanced solid tumors: Results of phase 1 study
Presenter: Alexander Starodub
Session: Poster Display
140P - Eliciting mAbs targeting MHC-bound peptides with a novel antibody discovery platform
Presenter: Elli Sandberg
Session: Poster Display
141P - An IgE antibody targeting the melanoma-associated Chondroitin Sulfate Proteoglycan 4
Presenter: Lais Cristina Palhares
Session: Poster Display
142P - Identifying novel immunotherapy targets using machine learning and ex vivo validation
Presenter: Marcellus Augustine
Session: Poster Display
143P - Advancing Cancer Immunotherapy via HLA-G Pathway Modulation with UCB4594
Presenter: Ann WHITE
Session: Poster Display
144P - Discovery of CBO421, a first-in-class Drug Fc-Conjugate (DFC), targeting CD73 in Cancer
Presenter: Simon Döhrmann
Session: Poster Display
145P - An Engineered Ligand-Trap Biologic Targeting the CD47 Signaling Pathway for Cancer Treatment with Superb Efficacy and Safety Profiles
Presenter: ZONG SEAN JUO
Session: Poster Display
146P - A Novel Allosteric Oral Immunotherapy Small Molecule Modulates Adenosine 2A Receptor Signaling and Restores Anti-Tumor Immune Responses
Presenter: David Pejoski
Session: Poster Display